Literature DB >> 36056946

Early-Onset Late Gadolinium Enhancement is a Prognostic Factor for Duchenne Cardiomyopathy.

Lorraine James1, Jondavid Menteer2,3, Lilith C Moss4,3, Ramon Durazo-Arvizu4,3, John C Wood2,3, Leigh Ramos-Platt5,3, Emmanuelle Tiongson5,3, Jennifer A Su2,3.   

Abstract

Dilated cardiomyopathy (DCM) is an inevitable complication of Duchenne muscular dystrophy (DMD). Late gadolinium enhancement (LGE) demonstrated by cardiac MRI occurs in DMD-related DCM, indicating myocyte death and remodeling. We conducted a retrospective chart review identifying DMD patients in our center between January 2009 and July 2013. Subjects were cohorted by presence of LGE before age 14. We excluded patients in whom we could not determine LGE status prior to age 14. We reviewed comprehensive clinical data. Of the 41 subjects with complete data, 15 demonstrated LGE before age 14 ("early LGE") and 26 had no LGE by age 14 ("controls"). Those with early LGE exhibited a more rapid decline in LV fractional shortening (p = 0.028). Patients with early LGE were younger at age of initiation of ACE inhibition (p = 0.025), mineralocorticoid receptor antagonism (p = 0.0024), and beta-blockade (p = 0.0017), suggesting aggressive clinical management in response to abnormal MRI findings. There were no significant differences in LV dilation between the two groups (p = 0.1547). Early LGE was not associated with obesity (p = 0.32), age at loss of ambulation (p = 0.31), or heart rate (p-value > 0.8). Early onset of myocardial fibrosis as indicated by LGE on cardiac MRI is associated with earlier progression of cardiomyopathic changes despite earlier medication therapy. Identifying this risk factor, observed in 34% of our cohort during preadolescence, may guide medical therapy and early counseling about cardiomyopathy progression. We advocate for obtaining at least one MRI in patients with DMD prior to age 14 to risk stratify patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiomyopathy; Duchenne; Genetics; MRI

Year:  2022        PMID: 36056946     DOI: 10.1007/s00246-022-02989-8

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.838


  17 in total

Review 1.  Cardiac involvement in muscular dystrophies: molecular mechanisms.

Authors:  Fiona C Goodwin; Francesco Muntoni
Journal:  Muscle Nerve       Date:  2005-11       Impact factor: 3.217

2.  The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy.

Authors:  G Nigro; L I Comi; L Politano; R J Bain
Journal:  Int J Cardiol       Date:  1990-03       Impact factor: 4.164

3.  Verapamil in Duchenne muscular dystrophy.

Authors:  A E Emery; R Skinner; L C Howden; M B Matthews
Journal:  Lancet       Date:  1982-03-06       Impact factor: 79.321

4.  Left Ventricular Tonic Contraction as a Novel Biomarker of Cardiomyopathy in Duchenne Muscular Dystrophy.

Authors:  Jennifer A Su; Leigh Ramos-Platt; JonDavid Menteer
Journal:  Pediatr Cardiol       Date:  2015-12-29       Impact factor: 1.655

5.  Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.

Authors:  Subha V Raman; Kan N Hor; Wojciech Mazur; Nancy J Halnon; John T Kissel; Xin He; Tam Tran; Suzanne Smart; Beth McCarthy; Michael D Taylor; John L Jefferies; Jill A Rafael-Fortney; Jeovanna Lowe; Sharon L Roble; Linda H Cripe
Journal:  Lancet Neurol       Date:  2014-12-30       Impact factor: 44.182

Review 6.  The muscular dystrophies.

Authors:  Alan E H Emery
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

7.  Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy.

Authors:  Marly Conceição Silva; Zilda Maria Alves Meira; Juliana Gurgel Giannetti; Marcelo Moreira da Silva; Alysson Félix Oliveira Campos; Márcia de Melo Barbosa; Geraldo Moll Starling Filho; Rogério de Aguiar Ferreira; Mayana Zatz; Carlos Eduardo Rochitte
Journal:  J Am Coll Cardiol       Date:  2007-04-23       Impact factor: 24.094

8.  Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy.

Authors:  Animesh Tandon; Chet R Villa; Kan N Hor; John L Jefferies; Zhiqian Gao; Jeffrey A Towbin; Brenda L Wong; Wojciech Mazur; Robert J Fleck; Joshua J Sticka; D Woodrow Benson; Michael D Taylor
Journal:  J Am Heart Assoc       Date:  2015-03-26       Impact factor: 5.501

9.  Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function.

Authors:  Kan N Hor; Michael D Taylor; Hussein R Al-Khalidi; Linda H Cripe; Subha V Raman; John L Jefferies; Robert O'Donnell; D Woodrow Benson; Wojciech Mazur
Journal:  J Cardiovasc Magn Reson       Date:  2013-12-21       Impact factor: 5.364

10.  Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients.

Authors:  Anca Florian; Anna Ludwig; Markus Engelen; Johannes Waltenberger; Sabine Rösch; Udo Sechtem; Ali Yilmaz
Journal:  J Cardiovasc Magn Reson       Date:  2014-09-25       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.